Blawg Search - Law Blogs, Lawyer Blogs, Legal Blogs Directory & Search Engine

The United State Attorney for Massachusetts reports in a press release that "Bristol-Myers Squibb Company (BMS) and its wholly owned subsidiary, Apothecon, Inc., have agreed to pay in excess of $515 million to resolve a broad array of federal and...

In another stirring chapter of the on-going Plavix debacle, the Bristol-Myers Squibb pleaded guilty to two criminal counts of two violations of the federal False Statements Act and will pay a $1 million fine (the maximum ... it to submit any proposed patent settlements for review and approval by the FTC. The FTC warned Bristol-Myers that it would not approve a settlement of the Plavix litigation if the company agreed not to launch its own generic version of Plavix that would compete against Apotex ...

... billion. With Medarex holding approximately $300 million in net cash and marketable securities, the purchase prices is effectively about $2.1 billion. Under the agreement, Bristol-Myers Squibb will commence a cash tender offer on or about July 27, 2009 to purchase all of the outstanding shares of common stock for $16.00 per share, and the companies expect the tender offer to close approximately 30 days after its commencement. ...

Article from WCVB TV/DT Boston -- Company To Pay $515M To Settle Drug Marketing Probes: Bristol-Myers Squibb Agrees To Settlement. Here's an excerpt: Bristol-Myers Squibb Co. and a subsidiary have agreed to pay more than $515 million to settle federal...

... Plaintiff not Entitled to give Notice of Litigation to Other Pharmaceutical Representatives of Bristol-Myers Squibb because Administrative Employee Exemption to Overtime Pay Likely Applies New ... Myers Squibb Co., ___ F.Supp.2d ___ (S.D.N.Y. June 4, 2008) [Slip Opn., at 2]. As part of her discovery ... all 4500 pharmaceutical representatives. Id. At a status conference, defense attorneys explained that the company's pharmaceutical representatives "include four levels of seniority and are employed by five ...

Back in the summer of 2006, drugmaker Bristol-Myers Squibb hit the skids when the feds investigated an agreement the company struck to delay the launch of a generic version of its blood-thinning drug, Plavix. The deal, which was ... Dolan and GC Richard Willard. Now, three years after the controversial deal with Apotex was made, the man who made it, a former Bristol VP, Dr. Andrew Bodnar, is being indicted for allegedly making a false statement to the Federal Trade Commission regarding the deal. ( ...

... but did not actually make the false statement. Employees within the company amounted to a possible category. The issue came up in In re Bristol Myers Squibb Co. Sec. Litig., 2008 U.S. Dist. LEXIS 63567 (SD NY Aug. 19, 2008 ... himself, but investors relied on his good faith in negotiating the Apotex settlement agreement and committing the Company to its terms. Furthermore, unlike in Stoneridge where the defendants' "deceptive acts were not communicated to the public," ...

A deal between Sanofi-Aventis, France's largest drug company, and U.S. rival Bristol-Myers Squibb could still be in the offing. The Times of London reports that if a battle of egos between Sanofi's chairman and its younger chief executive is resolved, the French company may dust off its $54 billion merger plans with Bristol-Myers. The [...]

A Department of Justice criminal investigation into an agreement between Bristol-Myers Squibb and generic drug-maker Apotex regarding a $40 million payment to the company to keep a generic version of Plavix, one of Bristol-Myers best selling drugs, from the market...

Bristol-Myers Squibb Co. announced that it has reached an agreement in principle with the Antitrust Division of the Department of Justice to plead guilty to two false statement charges for violating Sec. 1001. The case arose from the company's negotiations...